Wyeth Licenses Osteoporosis Drug Targets From Galapagos
Wyeth agrees to second milestone stemming from 2003 agreement, selecting three novel Galapagos targets for osteoporosis.
Wyeth agrees to second milestone stemming from 2003 agreement, selecting three novel Galapagos targets for osteoporosis.